Furthermore, we have shown that chronic HF patients carrying the ADRB2-Gly16 allele (AG or GG genotype) have a markedly increased beneficial response to βAR-blocker therapy in an allele-dose-dependent manner. Here, ADRB2 is linked to hydrops fetalis.